Questions Concerning the Clinical Translation of Cell-Based Interventions under an Innovation Pathway

Jeremy Sugarman

doi:10.1111/j.1748-720X.2012.00723.x

Questions Concerning the Clinical Translation of Cell-Based Interventions under an Innovation Pathway

Jeremy Sugarman

Academic Centers

Research output: Contribution to journal › Article › peer-review

Abstract

Stem cell-based innovation is one pathway to clinical translation that stands in contrast to clinical research and medical treatment. After reviewing recently issued guidelines for responsible innovation, this article examines the potential benefits and harms of using this pathway as well as practical barriers and conceptual concerns regarding it.

Original language	English (US)
Pages (from-to)	945-950
Number of pages	6
Journal	Journal of Law, Medicine and Ethics
Volume	40
Issue number	4
DOIs	https://doi.org/10.1111/j.1748-720X.2012.00723.x
State	Published - Dec 2012

ASJC Scopus subject areas

Issues, ethics and legal aspects
Health Policy

Access to Document

10.1111/j.1748-720X.2012.00723.x

Cite this

@article{55b26626d16e44ba881cf585ad5ffd38,

title = "Questions Concerning the Clinical Translation of Cell-Based Interventions under an Innovation Pathway",

abstract = "Stem cell-based innovation is one pathway to clinical translation that stands in contrast to clinical research and medical treatment. After reviewing recently issued guidelines for responsible innovation, this article examines the potential benefits and harms of using this pathway as well as practical barriers and conceptual concerns regarding it.",

author = "Jeremy Sugarman",

year = "2012",

month = dec,

doi = "10.1111/j.1748-720X.2012.00723.x",

language = "English (US)",

volume = "40",

pages = "945--950",

journal = "Law, medicine & health care : a publication of the American Society of Law & Medicine",

issn = "1073-1105",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Questions Concerning the Clinical Translation of Cell-Based Interventions under an Innovation Pathway

AU - Sugarman, Jeremy

PY - 2012/12

Y1 - 2012/12

N2 - Stem cell-based innovation is one pathway to clinical translation that stands in contrast to clinical research and medical treatment. After reviewing recently issued guidelines for responsible innovation, this article examines the potential benefits and harms of using this pathway as well as practical barriers and conceptual concerns regarding it.

AB - Stem cell-based innovation is one pathway to clinical translation that stands in contrast to clinical research and medical treatment. After reviewing recently issued guidelines for responsible innovation, this article examines the potential benefits and harms of using this pathway as well as practical barriers and conceptual concerns regarding it.

UR - http://www.scopus.com/inward/record.url?scp=84872162721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872162721&partnerID=8YFLogxK

U2 - 10.1111/j.1748-720X.2012.00723.x

DO - 10.1111/j.1748-720X.2012.00723.x

M3 - Article

C2 - 23289697

AN - SCOPUS:84872162721

VL - 40

SP - 945

EP - 950

JO - Law, medicine & health care : a publication of the American Society of Law & Medicine

JF - Law, medicine & health care : a publication of the American Society of Law & Medicine

SN - 1073-1105

IS - 4

ER -

Questions Concerning the Clinical Translation of Cell-Based Interventions under an Innovation Pathway

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this